◆ Market Data --:--
⛽ Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

NervGen Pharma Corp.

NGEN.V TSXV Healthcare Vancouver, Canada
Loading stock data...
Stock Performance
Price History
- Drag to select time range -
Market Data
Market Cap 451.5M
P/E Ratio -
52-Week High -
52-Week Low -
Avg Volume -
Beta -
Forward P/E -
Dividend Yield -
EV/Revenue -
Price/Book -
Business Overview

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

Healthcare Biotechnology TSXV
Key Financial Metrics
-
Revenue
-24.0M
Net Income
C$-0.36
EPS (Diluted)
-16.8M
Free Cash Flow
Profitability
Gross Margin -
Operating Margin -
Net Profit Margin -
EBITDA -24.8M
Returns & Efficiency
Return on Assets (ROA) -123.2%
Return on Equity (ROE) -931.7%
Dividend Yield -
Payout Ratio -
Financial Health
Total Assets 19.5M
Total Debt 105,603
Debt to Equity 0.04x
Current Ratio 1.12
Company Info
IndustryBiotechnology
HQVancouver, Canada
Fiscal Year End1735603200
CurrencyCAD
Websitewww.nervgen.com
Peers
7.9B
P/E: --
2.5B
P/E: 12.0
2.5B
P/E: 23.7
2.2B
P/E: 53.2
1.4B
P/E: 24.1
1.2B
P/E: --
1.1B
P/E: --
631.8M
P/E: --
Insider Activity
Sentiment Bullish
Shares Bought 2,619,524
Shares Sold 0
Total Transactions 19
SEDAR+ Filings
View All Filings
3
Annual Reports
12
Quarterly Reports
12
MD&A
70
News Releases
16
Material Changes
11
Prospectuses
6
Governance
26
Certifications
70
Other

● Interim financial statements/report – English.pdf
2025-11-24
● Interim financial statements/report – English.pdf
2025-08-26
● Interim financial statements/report – English.pdf
2024-11-14
● Interim financial statements/report – English.pdf
2023-11-09
● Interim financial statements/report – English.pdf
2023-08-09
View all 12 quarterly reports →

● Interim MD&A - English.pdf
2025-11-24
● Interim MD&A - English.pdf
2025-08-26
● Interim MD&A - English.pdf
2024-11-14
● Interim MD&A - English.pdf
2023-11-09
● Interim MD&A - English.pdf
2023-08-09
View all 12 md&a →

● News release - English.pdf
2026-02-12
● News release - English.pdf
2026-02-09
● News release - English.pdf
2026-01-08
● News release - English.pdf
2025-12-17
● News release - English.pdf
2025-12-12
View all 70 news releases →

● Material change report - English.pdf
2026-02-17
● Material change report - English.pdf
2026-01-08
● Material change report - English.pdf
2025-11-26
● Material change report - English.pdf
2025-07-25
● Material change report - English.pdf
2025-07-07
View all 16 material changes →

● Amendment to (or amended) final short form prospectus – English.pdf
2025-12-15
● Prospectus (non pricing) supplement (ATM) – English.pdf
2024-12-19
● Final short form prospectus – English.pdf
2024-11-25
● Preliminary short form prospectus – English.pdf
2024-11-04
● Final short form prospectus – English.pdf
2022-08-12
View all 11 prospectuses →

● Form of proxy - English.pdf
2022-08-30
● Management information circular - English.pdf
2022-08-30
● Management information circular - English.pdf
2020-09-02
● Form of proxy - English.pdf
2020-09-02
● Form of proxy - English.pdf
2019-08-08
View all 6 governance →

● 52-109FV2 - Certification of interim filings - CFO (E).pdf
2025-11-24
● 52-109FV2 - Certification of interim filings - CEO (E).pdf
2025-11-24
● 52-109FV2 - Certification of interim filings - CEO (E).pdf
2025-08-26
● 52-109FV2 - Certification of interim filings - CFO (E).pdf
2025-08-26
● 52-109FV2 - Certification of interim filings - CFO (E).pdf
2024-11-14
View all 26 certifications →

● Other.pdf
2026-02-13
● Notice of the meeting and record date - English.pdf
2026-02-13
● Other.pdf
2026-02-12
● Early warning report.pdf
2025-12-29
● Other.pdf
2025-12-17
View all 70 other →
Interactive Charts
Full Chart View
Company Profile
General Information
Company NameNervGen Pharma Corp.
TickerNGEN.V
ExchangeTSXV
SectorHealthcare
IndustryBiotechnology
HeadquartersVancouver, Canada
Fiscal Year End1735603200
CurrencyCAD
Websitewww.nervgen.com
Financial Summary
Market Cap451.5M
RevenueN/A
Net Income-24.0M
P/E RatioN/A
EPS (Diluted)C$-0.36
Net MarginN/A
ROE-931.7%
Dividend YieldN/A
Business Description
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
NEWS
Loading news...
TRENDING
Loading...